Can bone scans guide therapy with radium-223 dichloride for prostate cancer bone metastases?

about

Can bone scans guide therapy with radium-223 dichloride for prostate cancer bone metastases?

Item

http://www.wikidata.org/entity/Q58759090

description

im Januar 2018 veröffentlichter wissenschaftlicher Artikel

@de

wetenschappelijk artikel

@nl

наукова стаття, опублікована у 2018

@uk

name

Can bone scans guide therapy w ...... ostate cancer bone metastases?

@en

Can bone scans guide therapy w ...... ostate cancer bone metastases?

@nl

type

Item

label

Can bone scans guide therapy w ...... ostate cancer bone metastases?

@en

Can bone scans guide therapy w ...... ostate cancer bone metastases?

@nl

prefLabel

Can bone scans guide therapy w ...... ostate cancer bone metastases?

@en

Can bone scans guide therapy w ...... ostate cancer bone metastases?

@nl

P1476

Can bone scans guide therapy w ...... ostate cancer bone metastases?

@en

P2093

David Wan

http://www.w3.org/2001/XMLSchema#string

Isis Gayed

http://www.w3.org/2001/XMLSchema#string

Lydia Dawood

http://www.w3.org/2001/XMLSchema#string

Robert Amato

http://www.w3.org/2001/XMLSchema#string

Steven Canfield

http://www.w3.org/2001/XMLSchema#string

Usha Joseph

http://www.w3.org/2001/XMLSchema#string

Vivian Salama

http://www.w3.org/2001/XMLSchema#string

P2860

From palliative therapy to prolongation of survival: (223)RaCl2 in the treatment of bone metastases

Radium-223 dichloride in clinical practice: a review.

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer

Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial.

An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223

Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion.

The promise of targeted {alpha}-particle therapy.

Radium-223 for the treatment of castration-resistant prostate cancer.

The changing pattern of management for hormone-refractory, metastatic prostate cancer.

Impact of skeletal complications on patients' quality of life, mobility, and functional independence.

P304

3317-3324

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/CMAR.S166218

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P50

Chunyan Cai

P577

2018-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30233247

http://www.w3.org/2001/XMLSchema#string

P932

6135075

http://www.w3.org/2001/XMLSchema#string